Bio-Rad Laboratories (BIO) EPS (Weighted Average and Diluted) (2016 - 2026)
Bio-Rad Laboratories has reported EPS (Weighted Average and Diluted) over the past 18 years, most recently at -$19.55 for Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 953.71% to -$19.55 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.81 through Mar 2026, up 107.62% year-over-year, with the annual reading at $27.85 for FY2025, 142.61% up from the prior year.
- EPS (Weighted Average and Diluted) was -$19.55 for Q1 2026 at Bio-Rad Laboratories, down from $26.39 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $27.78 in Q4 2022 and troughed at -$112.5 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is $2.29 (2025), against an average of -$11.75.
- Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 541.21% in 2024 and then plummeted 953.71% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $27.78 in 2022, then tumbled by 56.3% to $12.14 in 2023, then tumbled by 310.63% to -$25.57 in 2024, then skyrocketed by 203.21% to $26.39 in 2025, then plummeted by 174.08% to -$19.55 in 2026.
- Per Business Quant, the three most recent readings for BIO's EPS (Weighted Average and Diluted) are -$19.55 (Q1 2026), $26.39 (Q4 2025), and -$12.7 (Q3 2025).